ABSTRACT
INTRODUCTION 1
Research into the use of deep learning with artificial neural networks (ANN) is being widely 2 undertaken. A key application is in radiology, particularly in the classification and 3 segmentation of biomedical images (1-4). ANNs have been trained and evaluated using x-4 ray computed tomography (CT) (5-7) and positron emission tomography (PET) imaging 10), and several magnetic resonance imaging (MRI) data types including structural T1-and 6 T2-weighted images (11), perfusion images (12), MR spectroscopy (13) and diffusion MRI 7 (14) . 8
In the last five years, convolutional neural networks (CNNs) have become by far the most 9 popular choice of deep learning architecture (15). CNNs allow subtle and abstract features to 10 be characterised, but often require very large, labelled data sets (16). As an alternative 11 approach, we propose using data-rich diffusion-weighted MRI acquisitions to define a 12 fingerprint in each voxel, which can easily be classified according to tissue type and used to 13 train a deep neural network. This approach aims to produce accurate diagnostic information 14 with a relatively small number of subjects, as every voxel is treated as an independent data 15 point to train the ANN, rather than using whole images (or patches from within images) as 16 used in CNN architectures. 17 Contrast in diffusion weighted MRI is dependent on the random motion of water molecules 18 and the structure of the underlying tissue microenvironment. Various multi-direction and 19 multi-b-value diffusion MRI protocols have been proposed which are better at resolving 20 complicated tissue microstructure compared to basic diffusion tensor imaging (DTI). HARDI 21 (high angular resolution diffusion weighted imaging) and NODDI (neurite orientation 22 dispersion and density imaging) use multiple diffusion directions (17,18) to improve 23 measurement of neuronal fibre direction, whilst VERDICT (vascular, extracellular and 24 restricted diffusion for cytometry in tumours) protocols employ multiple directions and 25 multiple sets of diffusion weighted scans (19, 20) to make estimates of cancer cell 26 microstructure and density. These types of diffusion MRI protocols are particularly amenable 27 minimise motion artefacts. Body temperature was maintained at physiological temperature 23 using a hot water system and monitored using a rectal probe (SA Instruments). Respiration 24 was monitored using a neonatal apnoea pad taped to the abdomen of the animal. For 25 gadolinium-based scans, an intraperitoneal infusion line was inserted into the mouse. 26
Diffusion MRI 1
Gliomas were localised using a structural spin-echo sequence. For generating the diffusion 2 fingerprints, diffusion-weighted images were acquired in a coronal orientation using a 3-shot 3 spin-echo echo planar imaging (EPI) sequence, with the following parameters: TR = 3s, TE 4 = min, DM = 64 2 , FOV = 20mm 2 , shots = 3, slice thickness = 0.5mm, slices = 5, averages = 5 2. In total, 46 diffusion weightings in 3 directions were acquired in addition to a 42 direction 6 DTI acquisition (b = 1000 s/mm 2 ). Specific gradient combinations are detailed in Table 1. TE  7 was minimised for all scans to maximise signal-to-noise. To correct for signal changes 8 caused by this variation in TE, an accompanying b = 0 s/mm 2 (B0) image was acquired for 9 every combination of diffusion gradients. Total acquisition time for all DWIs was 70 minutes. 10
Following diffusion imaging, mice were injected with gadolinium-DTPA (Magnevist). After 10 11 minutes -to allow for the contrast agent to circulate -slice-matched T1-weighted spin echo 12 EPI images were acquired. 
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Histology 1
To compare the DLDF category maps with a ground truth, histology was performed on the 2 mouse brains. After the final MRI scan, mice were terminally anaesthetised via 3 intraperitoneal injection of 100 mg/kg sodium pentobarbital (Pentoject, Animalcare, York, 4 UK) and then transcardially perfusion-fixed with 10 ml heparinised saline followed by 10 ml 5 4% paraformaldehyde (PFA). For histology, mouse brains were extracted, sliced in a coronal 6 orientation and stained with hematoxylin and eosin (H&E) and glial fibrillary acidic protein 7 (GFAP). 8
Labelling and Diffusion Fingerprint Preparation 9
Four tissue categories were manually identified on contrast-enhanced images: 1) 10 background (corresponding to any pixel that was not part of any other region), 2) normal-11 appearing brain, 3) untreated tumour (regions showing contrast-enhancement in all animals 12 at day 0 and only control animals at day 9) and 4) treated tumour at day 9 ( Figure 1a) . 13
Diffusion fingerprints consisting of 232 ordered data points, from individual pixels (Figure 2) 14 were produced for each pixel, and were normalised to an acquisition with no diffusion 15 encoding. 16
Deep Learning of Diffusion Fingerprints 17
We created a deep neural network with 5 hidden layers in Keras (a model-level library, 18 Python 3.5.2) using TensorFlow as the numerical backend (21). Each hidden layer was 19 regularized with 20% dropout (to avoid overfitting), and used rectified linear unit (ReLU) 20 activation and normally-distributed initialisation. The number of nodes for each layer was 21 100, 150, 200, 512 and 1024, respectively. The output layer contained 6 nodes 22 corresponding to the categories defined above. Diffusion fingerprints from individual pixels 23 were passed to the network input layer. 24
Training 1
50% of the data were randomly assigned to a training set, which were further refined to 2 include equal numbers of fingerprints from each category (a total of 6,608 fingerprints). 3
Training of the network was performed on a Nvidia Titan-X GPU, using stochastic gradient-4 descent optimisation (learning rate, 0.01; decay, 1e-6; momentum, 0.9), with mean squared 5 error loss function. Training was performed for 50,000 epochs, with 10,000 steps in each. 6
Evaluation 7
The evaluation data set contained 5 animals per group. Each diffusion fingerprint was 8 categorised by the deep learning network and reconstructed as category maps. Dropout 9 regularisation was used to estimate classification probability and variance via Monte Carlo 10 sampling (22). 11
RESULTS
12
Brain Region Classifiers and Diffusion Fingerprint Generation 13
Gliomas were hyperintense on T1-weighted post-gadolinium images compared to normal 14 brain at both day 0 and day 9 (Figure 1a The category masks were applied to the slice-matched diffusion data to generate the 1 diffusion fingerprints required for training the ANN. Figure 2a shows a complete dataset of 2 diffusion MR images from one coronal slice through a mouse brain. Image intensity 3 decreases as the level of diffusion-weighting is increased. Figure 2c shows diffusion 4 fingerprints from four different regions. Diffusion fingerprint 1 (blue) comes from a region 5 outside of the animal, hence the plot is a noisy trace. Diffusion fingerprint 2 (green) comes 6 from normal brain, whilst diffusion fingerprints 3 (yellow) and 4 (red) originate from untreated 7 and treated tumour, respectively. The first 48 points in each plot represent the DTI (plus six 8 B0) scans. The remaining points represent different combinations of diffusion gradients 9 (detailed in Table 1 ). Upon visual inspection, some differences can be observed in the 10 diffusion fingerprint from the normal brain compared to the fingerprints from the tumours. 
Model Accuracy 1
In total, 6,608 fingerprints from 50% of the animals were used to train the ANN. Training 2 lasted 80 hours, and resulted in a model accuracy of 98.65% (where pixels were classified 3 as the same category determined by manual segmentation). Based on evaluation of the 4 ANN using the remaining 50% of the imaging data, accuracy was 98.54% (once again, 5 compared to manually segmented data). 6
Voxel Classification 7
A strong agreement was observed between manually segmented category maps (Figure 1b)  8 and DLDF maps generated from the evaluation phase (Figure 1c ) demonstrating the ability 9 of the ANN to automatically segment tumour from normal brain. Predicted tumour volumes 10 were 2.1 ± 0.2 times larger than manually-segmented volumes. This is due in part to the 11 identification of tumour deposits that had grown beyond the skull. Ghosting artefact in 12 background regions was also miscategorised as brain or tumour tissue. 13
The ANN was able to reliably identify diffusion fingerprints corresponding to normal brain 14 (green), untreated tumour (yellow) or post-treatment tumour (red). Furthermore, the ANN 15 was able to distinguish between tumours based on age (Figure 1e ): voxels within day 0 16 tumours were predominantly classified as day 0 pixels (green, 92% accuracy), whilst 17 untreated and treated tumours were mostly classified as day 9 pixels (red, 93% accuracy). 18
Regardless of age, tissue outside of tumours was predominantly classified as normal brain 19 (purple, 97% accuracy). 20
In comparison, ADC alone was unable to correctly stratify all pre-therapy tumours from 21 untreated tumours by simple thresholding (Figure 3b ). Whilst the mean ADC value in the 22 pre-therapy tumours was significantly lower than the untreated tumours at day 9 (p < 0. Visual inspection of DLDF category maps from untreated tumours at day 9 (Figure 4a ) 1 revealed a more spiculated appearance than treated tumours at day 9 ( Figure 4b ) and 2 showed a strong spatial accordance with H&E-stained histological sections. Centralised 3 regions of normal brain pixels (green) and 'treated' pixels (red) were often observed inside 4 the untreated tumours. These regions could correspond to areas on histology (Figure 4c ) 5 which showed a mix of tumour cells, neuronal tissue and voids likely corresponding to cell 6 death. 7 DLDF category maps from treated animals generally showed a distinctive rim of 'untreated' 8 pixels (yellow) at the tumour periphery (Figure 4b ), which could correspond to border regions 9 in H&E images where the tumour transitions into the normal brain (Figure 4d ). Whether 10 these are regions that truly show less sensitivity to TMZ therapy requires further 11 investigation. 12 13 
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In some of the untreated animals ( Figure 5a , black arrows), the predicted category maps 1 showed tumour invasion into the contralateral hemisphere along the corpus callosum. 2 Histological sections from the same brains showed increased GFAP-staining along the 3 corpus callosum (Figure 5a ), whereas much less GFAP-staining was visible in untreated 4 (Figure 5b ) and treated (Figure 5c ) mouse brains, which displayed no evidence of tumour 5 invasion on DLDF category maps. 6
DISCUSSION 7
The aim of this study was to evaluate the ability of DLDF in a mouse brain tumour model to 8 categorise normal brain, pre-treatment, untreated and Temozolomide-treated tumour pixels. 9
We have shown that DLDF can automatically segment tumours from normal brain, DLDF 10 can automatically distinguish between young and older (after 9 days of growth) tumours and 11 that DLDF can detect whether or not a tumour has been treated with chemotherapy. We 12 have also shown that, spatially, the category maps generated by DLDF were broadly 13 consistent with histology and that interesting features are detected which may correspond to 14 transitional regions within tumours where the microstructure is a mixture of normal brain and 15 tumour cells. 16
The ANN used for DLDF was trained on only 6,608 fingerprints and achieved good 17 prediction and evaluation accuracies. Broadly, the shape of the tumours delineated using 18 DLDF were consistent with manually-segmented training data. Interestingly, during manual 19 segmentation of T1-weighted images, regions of enhancement above the bulk of the tumour 20 or even external to the skull, which were likely caused by deposition of tumour cells during 21 retraction of the inoculation needle, were not segmented as tumour, and yet these regions 22
were correctly labelled as tumour on DLDF category maps. 23
Likewise, we also found evidence in DLDF category maps for tumour invasion into the 24 contralateral hemisphere, via the corpus callosum, but only in control mice. This was 25 accompanied by a much more spiculated appearing boundary, which contrasted with the 26 smoother appearance of TMZ-treated tumours. No evidence of invasion was detected in 1 treated mouse brains, most likely as a direct result of TMZ causing growth inhibition. GFAP-2 stained histological slices from the same brains confirmed these regions of invasion, where 3 more intense staining was seen along the corpus callosum in the untreated animals. This 4 finding is of particular interest, as these invasion effects were not included in the manually 5 segmented ROIs used to train the ANN. It also presents a challenge in regard to quantifying 6 the accuracy of the ANN, as these, and other, correctly segmented and informative regions 7 actually serve to reduce the reported accuracy of the ANN. 8
Further deviations between manual segmentation and the DLDF category maps were 9 evident, and which were consistent with histology. Untreated tumours at day 9 contained 10 numerous voxels that were categorised as normal brain, and which were positioned in a 11 similar location to regions of brain tissue within the tumours. Likewise, voxels at the 12 periphery of TMZ-treated tumours were often misclassified as 'untreated'. This could be a 13 straightforward misclassification error by the ANN, or evidence of regions of tumour that 14 were less prone to changes in microstructure induced by Temozolomide, or even with a 15 potential for resistance. This could be an interesting area for further research, as 16 noninvasive biomarkers of treatment resistance would be particularly useful in the clinic for 17 monitoring response (23, 24) . 18
The DLDF results are also interesting as they appear to outperform an alternative, more 19 conventional approach to treatment monitoring, which is to apply simple thresholding to 20 mean tumour ADC measurements. Untreated brain tumours could be distinguished from 21 treated tumours based on their mean ADC, which was significantly higher in treated mice. 22
However, assessment of localised treatment response was not possible using ADC alone. In 23 treated mice, ADC was broadly elevated across the whole extent of tumour, however, 24 untreated mice exhibited localised regions of similarly elevated ADC, most likely 25 corresponding to regions of necrosis or (non-chemotherapy related) apoptosis. DLDF 26 provides a localised map of treatment response, possibly highlighting regions of non-1 responding, or chemotherapy resistant, tumour tissue. 2
The results presented in this study, although preliminary, show some of the potential for 3 deep learning on an individual voxel level, and could be applied to other types of multi-4 dimensional acquisitions. Even with limited training DLDF was able to accurately classify 5 normal brain, treated tumours and control tumours at two different time points, and in some 6 regards, was able to out-perform manual segmentation by identifying regions of tumour 7 invasion, mixed tissue types and, potentially, tumour regions that were less sensitive to 8 TMZ-treatment. The ability of DLDF to predict response to therapy and to 'age' tumour pixels 9 will be the focus of further investigation. 10 
TABLE CAPTIONS 1
